Thei ncidence of deathd ue to recurrent pulmonary embolism (PE) after afirst-time idiopathic PE is not well defined.We conductedaretrospectivestudy of patients age 18 to 56 years who had idiopathic PE between 1994-2001.Theincidence and cause of deathwithin fiveyears wasdetermined using linked discharge records andam asterd eath registry. At otal of 3,456p atients had af irst-time idiopathic PE.The rate of recurrent VTE 0-6 monthsa fter the index eventw as 13.1%/year, and 2.9%/year 6-60 monthsafter the event. During the mean follow-up of 3.2 years 118( 3.4%,9 5% confidence interval [CI]=2.8-4.1%) patientsdied. Fifty-two(44%)deaths occurred<29 days afterthe index PE (case-fatality rate =1.5%,95%CI=1.1-2.0%). Among the 66 cases (1.9%) that died after 28 days, 18 (0.52%) were dueto Keywords Thromboembolism, epidemiology,P E, venous thrombosis,a dministrativedata recurrent PE or its sequelae: eight had recurrent PE alone, five had recurrent PE andas erious co-morbid illness, andf iveh ad thromboembolic pulmonary hypertension with or without acute PE.The person-time rate of death (deaths per100 patientyears) attributed to anyr ecurrent thromboembolism6 -60 monthsa fter the eventw as 0.16%( 95%CI=0.1-0.26%). Te no f the 18 (56%) latethromboembolic deaths reflected afirst-time recurrent PE.The 28-daycase-fatality rate forrecurrentVTE was 2.8% (95%CI=1.5-4.9%).Inthis cohortofyoungerpatientswith idiopathic PE,the rate of death due to recurrentVTE,particularly to first-time recurrent PE,was low.Among thepatientswho died of thromboembolism >28daysafter the index PE,28% had developed pulmonary hypertension.
Introduction
One of themost difficultquestions that aclinicianfaces when treating ayounger patient with idiopathic pulmonaryembolism (PE) is whether to continue oral anticoagulation indefinitelyor to discontinue therapyatthe end of the three-to six-month treatment period that is generallyr ecommended ( 1) . An umber of studies have addressedthe decision making that is involved,and this process depends on an accurate estimation of five clinical outcomes: i) the risk of bleeding if anticoagulation therapyi s continued, ii) the risk of recurrent venous thromboembolism (VTE) if anticoagulation is stopped,iii) the risk thatarecurrent VTE will be manifestasPEversus deep vein thrombosis (DVT), iv)the morbidityofarecurrent DVTevent, and v) the case-fatality rate of recurrent PE (2) (3) (4) . Although prior studieshaveprovided estimateso ft he incidenceo ft he first fourc linical outcomes,thereisapaucity of reliable data regarding both the incidenceand case-fatality rate of recurrent PE,particularlyamong generallyh ealthyy ounger individuals whoh avef ew or no chronic co-morbid medicalconditions There is no perfect and unbiasedmethodtoaccuratelydetermine the incidencea nd case-fatality rate of recurrent PE in younger patients with idiopathic PE. Prospective cohorts (5), registries (6, 7) , and clinical trials (8) , are prone to variousforms of case selection bias, particularlyb ecauset heyo ften exclude sicker patients and include onlyasmall number of younger individuals. Observationalstudiesfrequently lack sufficient sample size or duration of follow-up, theymay not be able to identify all the deaths (9, 10) , and theymay extend over suchalong timeframe that thereissignificant variation in clinical practice (11) . Perhapst he twom ost significant limitations to the studiest hat have beenpublished to date arethe absence of follow-up beyond the initial treatment period and the absence of information about the presenceorabsenceofcoexisting acute or chronic co-morbid disease (12) (13) (14) (15) .Douketis et al. recentlyreported the incidence of fatalPEinacohortof2,052 VTE patients treatedwith oral coagulants for an averageofsix months, buttheir cohortwas older (mean age 62 years)and the majority (70%)were diagnosed with DVTalone,not PE (16) .
The aim of the present study wastodetermine both the shortterm (0-6months) and long-term(>6 months) incidencedeath duetorecurrentthromboembolicdiseaseamong younger "healthier" patients diagnosedw ith af irst-time idiopathicP E. Although no information wasa vailabler egarding chronic anticoagulation treatment, basedo nl arge cohorts tudiesf rom the late 1990s we expected that fewerthan 20% of cases would be expected to remain on oralanticoagulant therapybeyond 6-12 months.Byfocusing onlyonpatients under the age of 56 years whohad at most one co-morbid condition, we aimedtominimize the number of patients whoh ad multiple chronic medical comorbid conditions.Byusing the comprehensive linked California patient discharge datas et linked to the state's masterd eath registry, we identifiedall hospitalizations between the initialPE event and death, and determinedthe presenceorabsenceofacute or chronic co-morbid illnesses.
Methods

Database
The California Patient DischargeData Set hasbeen described in detail in other manuscripts (17) .All non-federal hospitals supply specificinformation about each inpatient, including basicdemographic data,the principaldiagnosis, up to 24 secondary diagnoses, aprincipalprocedure, andupto20secondary proceduresusing International Classification of Diseases, 9th Revision,C linical Modification (ICD-9-CM) codes. SinceJulyof1990 the useofan encryptedr ecord linkage number has allowed serial hospitalizations to be linked.Diagnoses arebased on conditions listed by the physicians caringf or the patient, anda re not based on specific criteria. Fore xample, ad iagnosiso fo besity is notb ased on the body mass index (BMI), butonlythe physician'swritten opinion. Thes tudyw as approvedb yt he California Health and We lfare Agency Committee forthe Protection of Human Subjects,and the University of California, Davis Human Subjects Committee.
Cohortfirst-time idiopathicPE
Forinclusion, cases had to be 18 to 56 years old, have aprincipal diagnosis of PE (ICD-9-CMcode, 415.1x), or aprincipal diagnosiso fD VT (451.1x;4 51.2; 451.81; 451.9; 453.1; 453.2; 453.8; and 453.9) plus asecondarydiagnosis of PE, and be hospitalized between Jan1 ,1994-Sept 30, 2001 . To include only cases with afirst-time PE, allc ases thath ad ap rior historyo f VTE (= specific codes) or thepresence of aV12.51 or V12.52 code (past historyofVTE) backtoJuly1,1990 were excluded. Idiopathic PE wasdefinedasaPEinthe absence of aprovoking risk factor,s pecifically: i) diagnosis of an active cancer (ICD-9-CM codes)within one year prior to admission or within four monthsf ollowing the date of admission (18) ,i i) ap receding medical or surgical hospitalization (including trauma) within three months, iii) arecent or ongoing pregnancy(no delivery of anewbornwithin 3months prior to or 9months following the dayofadmission) and iv)adiagnosis of chronic pulmonary hypertension or pulmonaryheartdisease(416.0, 416.8, 416.9) at the timeoforprior to the indexhospitalization. We assumedthat in the late 1990s that all cases with acute PE would have been hospitalizedf or at least threed ayst or eceive parenterala nticoagulant therapy. Therefore,c ases coded as having acuteP E thatw ere hospitalized forl esst han threed ays( unless the case died on hospital day0,1or2)were excluded because theymore likelyreflected acoding error than true PE. No specific information wasavailableregarding the presence or absence of an underlying thrombophilic disorder.
Recurrent thromboembolism
RecurrentVTE wasdefined as readmissiontoahospital with aprincipal diagnosis of DVTorPEorsuddendeath outsidethe hospital that wasadjudicated to be due to thromboembolism. RecurrentVTE events were classified in thesame fashionasthe indexevent,with cases codeda sh avingo nlyaDVTc lassified as having recurrent DVTw hereascases codedashavingaPE alone or PE withD VT were classified as having arecurrentPEevent.The numberofcases that developedrecurrentVTE duringthe indexhospitalization could not be determined.Recurrenteventsoccurringsix or more months after theindexevent were labeled "long-term".
Concurrentchronicmedical co-morbidity
In order to assemble as ufficiently larges tudy cohort, patients with one chronic co-morbidity were included, butt om inimize the effect of multiple co-morbiditiesonthe incidenceofrecurrentVTE (19) , patientswith morethan one chronic co-morbidity were excluded. Presence of chronic medical co-morbidity was determinedu sing am odification of the Healthcare Costsa nd Utilization Project(aka, 'Elixhauserindex') co-morbiditysoftware. 3.1(Sept 2005 version) (20) (21) (22) . Use of this co-morbidity indexhas been described in previous reports (19, 23) . Information from the indexhospital stayaswellasany hospitalizations in the prior 12 months wasusedtodefine the presence of aco-morbid condition (24) .I ns tudiest hat analyzed the validity of comorbidity data,m isclassification wasr are, and there wasv ery good agreement between the administratived ataa nd chart review data (22, 25) .
Bleeding
Major bleeding wasdefinedasahospital admission with aprincipal diagnosis of intraocular, intracranial, esophageal,g astric, gastrointestinal, renal, intra-articular, or pulmonaryb leeding using specificI CD-9-CMc odes (26) .H ematuria wasn ot includedsincemost cases reflect minor bleeding.
Deaths
Deaths were identifiedu sing the linked State of California Master deathfile,which identifies the cause of all deaths of California residents both within the state and outside of the state. The cause of death that is listed on the death certificateisdetermined by the NationalCenter forHealth Statisticsand mappedinto an ICD-10 code.This data base includes avariable indicating if an autopsy wasperformed. Theadjudicatedcauseofdeathfor each case wasdeterminedbyreviewofthe death certificatecauseof death coupledwith adetailedanalysis the terminal hospital discharged iagnosesa nd all prior hospital discharged iagnoses. Eighty percent of the deaths thatoccurred within the five-year follow-up period occurred in ahospital, allowing direct comparison of hospital diagnosesw ith the causeo fd eathl istedo nt he death certificate. Deaths were categorized as being caused by recurrent thromboembolism or unrelated to thromboembolism (e.g.admitted for acute myocardialinfarction, death certificate listing acuteinfarction as cause of death). The thromboembolism deaths were classified as:i)due to acute recurrent PE alone (outof-hospital death with PE listed as cause of death on the death certificate, or suddenunexplained death, or hospital admission for PE and death <30days), ii) due to recurrentPEcoupled with aseriousacuteorchronic medicalillness (admission for recurrent PE coupled with recurrent hospitalizations for achronic illness such as human immunodeficiencyv irus (HIV), lupus erythematosus,e tc., and iii) due to pulmonary hypertension diagnosedafter recurrent PE,with or without arecurrentacute PE at the time of death.
Out-of-hospitaldeaths thathad adeathcertificatediagnosis of cancer or achronic medicalproblemthat had beenidentified during ap rior hospitalization, sucha sH IV or cardiomyopathy etc., were assumed to have died of the specified chronic disease. In ordertoavoid misclassifying anycasethat potentiallydiedof acuterecurrentPE, all cases that died out of hospital withanonspecific cause of death on the death certificate(suchas'atherosclerosis') thatdid not have an autopsy,and that had acauseof death that wasnot consistent with anyprior medical diagnoses were assumed to have died of an acute PE. Twoo ft he authors (RHW,SM) reviewedthis information for all deaths, and assignment of the final adjudicated cause of death wasdeterminedby consensus. Deaths within 28 days of eitherthe indexorthe recurrent VTE event were used to calculatethe case-fatality rate.
Statistics
All death rates were calculatedasanincidence density in persontime, equaltothe number of patients dying per 100 patients living one year,a nd expressed as the percent patients dying per year.C ategorical data wasa nalyzedu sing Chi 2 -testing. Differences in person-time rates were compared using at wo-tailed mid-Pexacttest. Confidencelimits on rate datawere computed usingO penEpi (27) ,K aplan Meier methods were used to plot survivala nd incidenceo fr ecurrentV TE. Analyses were performedu sing SAS (version 9.2)a nd at wo-sided p-valuel ess than0.05 wasconsideredstatistically significant.
Results
During thestudy period,10,629 cases were admittedtoCalifornia hospitals for afirst-time idiopathicPE. Of these cases, 3,456 satisfied the entrancecriteriaofbeing 55 years or younger and having at most just one chronic co-morbid medicalc ondition. The demographic and clinical characteristics of this cohortare showninTable 1. Thefrequencyofthe most common chronic co- morbiditiesthat were present at the time of the indexhospitalization is shown in Table2.The meanage was42±9years,50% of the cases were men, 73% were Caucasian, and the mean followup time was3.2 years (91days-5years).
Recurrent VTE events
There were atotal of 448 (12%,CI=11.8%-14%) cases with recurrent VTE.Ofthese,441 cases were hospitalized with arecurrentVTE, 68% were diagnosed as PE and 32%asD VT alone. Sevenadditional cases had recurrent PE butdiedout-of-hospital: five had adeathcertificatediagnosis of thromboembolism (n=5) and twowere adjudicated to have died due to recurrent PE. The incidenceofrecurrentPEa nd death during the study period is depicted schematicallyinFigure1.Therewere 100(22%) cases with recurrent VTE during days 0-28, 104 (23%)between days 29 and 182a nd 244 (54%)b etween six months and five years after the indexevent. The annualized rate (= events/100 patients/ year) of recurrent VTEi nm onths 0-6 months after the index event was1 3.1% per year (CI=11.4%-15%)w hereasf rom six monthstofiveyears the rate was2.9% (CI=2.5-3.2%) per year. AKaplan-Meier plot of the incidenceoffirst-time recurrent PE eventsisshown in Figure 2 .
Deaths
During thes tudy period 118( 3.4%, CI=2.8-4.1%) cases died and 40 of these cases underwent autopsy.AKaplan-Meier plot of survivalfrom the initialhospitalization for PE is shown in Figure  3 . Fifty-two (43%) of the deaths occurred within 28 days of the indexh ospital admission for PE (case-fatalityr ate=1 .5%). Fifty-one of these deaths occurred during the indexhospitalization, and 30 (58%)ofthese occurredonthe first or second hospitalday.Fifty of the 51 hospitaldeaths had PE listedasthe cause of death on the death certificatediagnosis, and 25 of these had undergone autopsy.The remaining patient had mastoiditis listed as the cause of death, whichoccurred on the 6 th hospital day. One patient died of major bleeding twodaysafter hospitaldischarge. Of the 50 patients whodiedwithin 28 days and whohad PE listed as the causeofdeath, 11 (22%)had aseriousunderlying medical illness (e.g.n euromuscular disease, sickle-celld isease, sepsis etc.),2 4( 48%) had ac hronic co-morbid conditions, and 17 (34%)had no other medical condition listed Among the 66 (1.9%) laterdeaths thatoccurred 29 or more days after the indexhospitalization, 18 were adjudicated as being caused by eitherrecurrentPEalone (n=8), recurrent PE coupled with asignificant underlying co-morbid condition (n=5), or recurrent PE leading to pulmonary hypertension, with death due to either ar ecurrentP Eo rh eartf ailure( n=5). Death certificates listedt hromboembolism as the cause of death in 14 of the 18 cases: six cases with PE, threec ases with DVTa nd five cases with pulmonary hypertension. Five of the 18 cases had undergone autopsy.The four remaining cases that were classified as thromboembolic deaths had deathcertificatediagnosesofmyocardialinfarction, hypertension, uncomplicated diabetes and anoxic braindamage. Theselater four cases were adjudicated to be likelydue to PE because theyeitherdiedsuddenlyout of the hospital (n=2), presentedwith cardiacarrest(n=1), or were admitted to ahospital for recurrent PE and died within threedays(n=1). None of these cases underwent autopsy.In10ofthe 18 (56%) late deaths attributed to recurrent thromboembolism,the death wasa ssociatedw ith af irst-time recurrent thromboembolic event,a nd seveno ft hese cases died out-of-hospital, whereas three were admitteda nd died in-hospital. Among the five patients whodieddue to thromboembolic pulmonaryhypertension with or without an acute PE, four were men, and the average numberofdaysbetween the indexevent and death was741 days ±530 (range 286-1,652). Theperson-time rate of death(deaths per 100 patient-years) duet or ecurrentP Eb etween three to six months, sevent o1 2 months, 13 to 24 months, and 25 to 60 monthsafter the indexPE event was0 .13% (CI=0.06-0.6%),0 .13% (CI=0.02-0.43%), 0.19% (CI=0.07-0.42%),and 0.17% (CI=0.08-0.32%),respectively. The annualized rate (= events/100 patients/year) of death duetoPEinmonths 0-6 months after the indexevent was3.2% per year (CI=2.4%-4.2%) whereas fromsix monthstofiveyears the rate was0.16% (CI=0.1-0.26%) per year.
Amongthe 48 later deaths more than 29 days after the index PE that were adjudicated to be unrelated to VTE, the causeo f death listed on the death certificatewas major bleeding in three cases,cardiacdiseaseinseven, cancer in seven, HIVinsix, infection or sepsisinfour,sickle celldiseaseinthree, chronic neurologicaldiseaseinfour,strokeintwo,chronic lung disease in two, and other conditions in 10, including systemic lupus, chronic kidneyd isease, hepatitis Ca nd suicide. Teno ft hese cases had undergone autopsy.Inthe majority of these cases, the cause of death on the death certificatewas listedasaconcurrent medicalcondition during either the indexhospitalization for PE or one of the intervening hospitalizations,indicating ahigh degree of diagnostic consistency. In eight cases,however,the death certificatelistedadiagnosis thatwas notlistedasanactivemedical problemduring anyprior hospitalization. However, alleight of these cases died moret han 550 days after the indexe vent (range=1.5-4.8 years), and sevenofthem had no hospitalization recordwithin ayear prior to death. However, six of the eighthad undergone an autopsy,lending credence to the deathcertificate diagnosis .
Death in relationship to recurrent VTE
Of the448 cases with recurrent VTE, 23 (5.2%)diedduring the follow-up period,and 12 of these cases died within 28 days of the recurrent event (case-fatality rate =2.7%, 95%CI =1.4-4.6%). Three cases died of bleeding morethan 28 days after the index hospitalization for PE, one with an intra-cerebralbleed and one with adeathcertificatediagnosis of a'coagulation defect' that underwent autopsy,and anothercaseofintracranialbleeding.
Bleeding
Discussion
The aim of thisretrospectiveobservationalstudy wastoestimate the incidenceofdeathdue to recurrent PE betweensix months and five years followingdiagnosis of acuteidiopathic PE in acohortofyounger healthier patients. Because therewas no specific information availableregarding the duration or intensity of oral anticoagulant therapyinthese patients, inferencesregarding the inherent risk of fatalr ecurrentP Eo ff anticoagulation therapy can notbemade, and this will requireprospectiveclinical trials. Nevertheless, the findings of this study arevaluable becausethe cohortstudiedwas population-based, racially/ethnically heterogeneous and the outcome of death could be readilyascertained. Thefindings reflect the "real world" incidenceofdeathfollowing afirst-time diagnosis of unprovokedPEinpatient treated in the community.The resultsofthis study when coupled with the findings of prospective clinical trials, provide important information thath elpi nformc linicians about the long-termr isk of deathdue to recurrent PE in similar patients.
The major finding of this study wasthat the overallincidence of death during or following the indexhospitalization for idiopathic PE waslow,and the incidenceofdeathdue to recurrent thromboembolic disease wasq uite rare.O nly1 18 (3.5%)p atients in this younger,h ealthierc ohortd iedd uring the average follow-up period of 3.2y ears,and close to half of these deaths (44%)o ccurred during the indexh ospital stay. Nevertheless, therewere 66 late deaths thatoccurred morethan 28 days after the initial indexPEevent and 18 (27% of late deaths, 0.5% of the entire cohort) of these were judged to have likelydiedasaconsequence of either an acute recurrent PE (n=13) or PE coupled with development of pulmonary hypertension (n=5). Only10of the thromboembolic deaths (0.3%o ft he total cohort) were judged to be aresultofafirst-time recurrent VTE event.The remaining eight cases had one or more hospitalization for recurrent VTE betweenthe indexPEhospitalization and the event that ledtodeath. Overall, the annualized rateofdeaththat could be attributed to recurrent thromboembolic disease wasv eryc onstant, ranging between0.13%-0.19% starting threemonths after the indexP Ee vent and going out to five years after the index event.This rate wasslightlylower thanthe rate of fatalrecurrent PE that wasrecently estimatedbyDouketis et al., 0.2%-0.5% per year,who studied an older cohortofpatients (16) .
Anotheri mportant findings wast hat 68% of all of the patients whowere hospitalized forrecurrentVTE eventswere diagnosedashaving aPE, whichisconsistent with the observation thatpatients whopresentwith an indexPEevent aremuch more likelyt ob ed evelop recurrent PE compared to aD VT (28) . A third important finding wasthat in this younger healthier cohort, the 28-dayc ase-fatality rate for first-time recurrent VTE was quite low, only2.7%.
An oteworthy finding wast hat five of the 18 patients that died of recurrent thromboembolism were classified as having chronic pulmonary hypertension, as each had at least one hospitalization for recurrent PE event and were subsequently diagnosed with pulmonaryhypertension (29) .None of these patients had adiagnosis of pulmonary hypertension before or at the time of the indexPEevent. Interestingly, fourofthe five were menand the deaths occurredanaverage of approximately twoyears after the indexe vent. It is possible that some of the cases that died suddenlyo ut of the hospital had pulmonaryh ypertension, although this wasnot listed as the cause of death on their death certificate. Thesef indings suggests thatp atients with chronic thromboembolic pulmonary hypertension makeupanappreciable percentage of the deaths caused by thromboembolic disease, and thatmost of these patients have one or more hospitalization for recurrent PE before the pulmonaryh ypertension becomesclinically evident. In arecent study by Pengo et al. (30) , the incidenceofchronic thromboembolic pulmonaryhypertension (CTPH) within twoyears after an indexPEwas 4%.Future prospective studiesare needed to determine howfrequently pulmonaryhypertension develops after asingle episode of PE versus multiple episodesofPE.
In thislarge population-basedstudy,the 28-daycase-fatality rate after afirst-time PE was1.5% and the six-month case-fatality rate was1.7%. This is significantly lowerthan the earlydeath rateof8.1% recentlyreported in amuch smaller and older cohort of patients diagnosed with acute PE (30) .H owever,t he casefatality rate thatweobservedwas closetothe three-month case fatality rate of 2.3% thatwas reportedinalarge meta-analysis of patients being treated forPEbyDouketis et al. (8) .The lowcasefatality rate thatweobservedinthe present study likelyreflects the lowerlethality of recurrent PE in patientsunder the age of 55 whohaveatmost one chronic medicalco-morbidity.
There were several important limitations to this study. First, we were able to analyze only patients whosurvivedsufficiently long to be admittedtoanacutecare hospital and be diagnosed with acutePE. Second, it is likelythat amodest percentage of the cases did not have objectively confirmed PE becauseofthe inherent inaccuracyofthe diagnostic tests (lung scanning and first generation computedtomography[CT] scanning) thatwere used during the time period studied, 1994-2001 (31, 32) . However, one careful retrospective study from the early1990s found little evidenceofo verdiagnosis of PE (33) . Nevertheless, to the degree thatPEwas over-diagnosed, the risk of deathdue to recurrent PE would have beenunderestimated. Third,wedid not have anyi nformation about the presenceo ra bsenceo fat hrombophilicdisorder.
Another limitationofthis study wasthe absence of anyinformation about long-termu se of oral anticoagulants. During the time of this study, from 1994 through2001, long-termuse of oral anticoagulation after an initialepisode of VTE wasnot standard in the United Statesorany other country. An estimate of thepercentage of patients treated forVTE for longer than sixmonths wasr ecently provided by Prandonie ta l. in as tudy from Italy. Among 1,600 patients withoutc ancer whow ere treated fora first-time VTEe vent between1991 and 2003, only17% of the cases were treated with oral anticoagulation for over six months, and less than5%were treated foroverayear (34) .Ifone assumes that 20% of the patients in the current study were maintainedon chronic oral anticoagulation indefinitelya nd that that chronic anticoagulation treatment was90% effective in preventing recurrent VTE (35,3 6) , the resultso ft he current study mayh ave underestimated the true rate of recurrent VTE and death six months to five years after the indexVTE event by approximately 20%. Thus, the estimated annualr ateo fd eathf rom recurrent thromboembolism maybeclosertobetween 0.20 to 0.35deaths per 100patients peryear.
Although an effort wasmade to select only younger,healthier patients with PE, approximately 40% had at least one chronic medicalco-morbid condition listed in their hospital records and manypatients hadasignificant underlying medical disease, such as lupuse rythematosus, chronic cardiomyopathy, amyotrophic lateral sclerosis or sickle celldisease. In fact at the time of death, only eightofthe 18 patients whose death wasattributedtorecurrentVTE had no evidenceofasignificant medical co-morbid illness. Five had an underlying chronic illness and five had pulmonaryhypertension. Further researchisneeded to determine to what degree underlying chronic co-morbidity contributestothe risk of recurrent VTE, particularlyfatal PE.
Although theyearlyincidence rate of fatalrecurrentPEwas very low, the observedincidence of death due to fatalbleeding even lower, as only one patient died of hemorrhage in the first six monthsafter the indexevent, and onlythreeadditional patients died of bleeding beyond six months.However,lacking dataabout the use or non-use of anticoagulation therapyitisimpossible to estimate the relativer isk of deathd ue to bleeding versust he death due to recurrent thrombosis.
In conclusion, in this population-based analysis of younger healthier patients diagnosed with acute idiopathic PE, the incidenceofdeathdue to first-time recurrent thromboembolism between onem onth and five years followingd iagnosis wasv ery low, occurring in only10of3,456 patients (0.3%). Overall, only 18 (0.5%)patients thatdiedmore than 28 days after their index hospitalisation died of recurrent thromboembolism during the followupperiod thataveraged 3.2years.Among the patients that diedo fr ecurrentt hromboembolism, death wasa ttributedt o thromboembolic pulmonary hypertension with or without acute recurrent PE in 28%. This rather high proportion of deaths due to pulmonaryhypertension supports the recommendation (29, 30) that patients with PE should undergo astandardized evaluation at the end of the period of anticoagulation treatment to determine the presence or absence of chronic unresolvedPEleading to pulmonary hypertension.
